I-06 Elisabeth Rouits Population pharmacokinetic model for Debio 1143, a novel antagonist of IAPs in cancer treatment Wednesday 10:05-11:40 |
I-10 Maria Luisa Sardu Tumour Growth Inhibition In Preclinical Animal Studies: Steady-State Analysis Of Biomarker-Driven Models. Wednesday 10:05-11:40 |
I-11 Emilie Schindler PKPD-Modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size following axitinib treatment in metastatic renal cell carcinoma (mRCC) patients Wednesday 10:05-11:40 |
I-36 Iñaki F. Trocóniz Modelling and simulation applied to personalised medicine Wednesday 10:05-11:40 |
I-41 Georgia Valsami Population exchangeability in Bayesian dose individualization of oral Busulfan Wednesday 10:05-11:40 |
I-43 Coen van Hasselt Design and analysis of studies investigating the pharmacokinetics of anti-cancer agents during pregnancy Wednesday 10:05-11:40 |
I-52 Camille Vong Semi-mechanistic PKPD model of thrombocytopenia characterizing the effect of a new histone deacetylase inhibitor (HDACi) in development, in co-administration with doxorubicin. Wednesday 10:05-11:40 |
I-58 Mélanie Wilbaux A drug-independent model predicting Progression-Free Survival to support early drug development in recurrent ovarian cancer Wednesday 10:05-11:40 |
II-09 Eric Fernandez drugCARD: a database of anti-cancer treatment regimens and drug combinations Wednesday 14:50-16:20 |
II-24 Pascal Girard Tumor size model and survival analysis of cetuximab and various cytotoxics in patients treated for metastatic colorectal cancer Wednesday 14:50-16:20 |
II-26 Timothy Goggin Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. Wednesday 14:50-16:20 |
II-31 Verena Gotta Simulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients Wednesday 14:50-16:20 |
II-38 Emilie Hénin Optimization of sorafenib dosing regimen using the concept of utility Wednesday 14:50-16:20 |
III-01 Stefanie Kraff Excel®-Based Tools for Pharmacokinetically Guided Dose Adjustment of Paclitaxel and Docetaxel Thursday 10:05-11:35 |
III-10 Junghoon Lee Modeling Targeted Therapies in Oncology: Incorporation of Cell-cycle into a Tumor Growth Inhibition Model Thursday 10:05-11:35 |
III-18 Hyeong-Seok Lim Pharmacokinetics of S-1, an Oral 5-Fluorouracil Agent in Patients with Gastric Surgery Thursday 10:05-11:35 |
III-25 Paolo Magni A PK-PD model of tumor growth after administration of an anti-angiogenic agent given alone or in combination therapies in xenograft mice Thursday 10:05-11:35 |
III-26 Mathilde Marchand Population Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Daratumumab in Multiple Myeloma Patients Thursday 10:05-11:35 |
III-27 Eleonora Marostica Population Pharmacokinetic Model of Ibrutinib, a BTK Inhibitor for the Treatment of B-cell malignancies Thursday 10:05-11:35 |
III-31 Pauline Mazzocco Modeling tumor dynamics and overall survival in patients with low-grade gliomas treated with temozolomide. Thursday 10:05-11:35 |
III-32 Litaty Céphanoée Mbatchi A PK-PGx study of irinotecan: influence of genetic polymorphisms of xenoreceptors CAR (NR1I3) and PXR (NR1I2) on PK parameters Thursday 10:05-11:35 |
III-34 Christophe Meille Modeling of Erlotinib Effect on Cell Growth Measured by in vitro Impedance-based Real-Time Cell Analysis Thursday 10:05-11:35 |
III-35 Olesya Melnichenko Characterizing the dose-efficacy relationship for anti-cancer drugs using longitudinal solid tumor modeling Thursday 10:05-11:35 |
III-55 Ignacio Ortega Application of allometric techniques to predict F10503LO1 PK parameters in human Thursday 10:05-11:35 |
III-58 Zinnia Parra-Guillen Population semi-mechanistic modelling of tumour response elicited by Immune-stimulatory based therapeutics in mice Thursday 10:05-11:35 |
III-64 Angelica Quartino Evaluation of Tumor Size Metrics to Predict Survival in Advanced Gastric Cancer Thursday 10:05-11:35 |
IV-13 Guillaume Baneyx Modeling Erlotinib and Gefitinib in Vitro Penetration through Multiple Layers of Epidermoid and Colorectal Human Carcinoma Cells Thursday 14:55-16:20 |
IV-28 Brigitte Brockhaus Semi-mechanistic model-based drug development of EMD 525797 (DI17E6), a novel anti-αv integrin monoclonal antibody Thursday 14:55-16:20 |
IV-31 Núria Buil Bruna Modelling LDH dynamics to assess clinical response as an alternative to tumour size in SCLC patients Thursday 14:55-16:20 |
IV-37 Quentin Chalret du Rieu Hematological toxicity modelling of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor, in patients suffering from solid tumors or lymphoma: influence of the disease-progression on the drug-induced thrombocytopenia. Thursday 14:55-16:20 |
IV-40 Christophe Chassagnole Virtual Tumour Clinical: Literature example Thursday 14:55-16:20 |
IV-53 Damien Cronier PK/PD relationship of the monoclonal anti-BAFF antibody tabalumab in combination with bortezomib in patients with previously treated multiple myeloma: comparison of serum M-protein and serum Free Light Chains as predictor of Progression Free Survival Thursday 14:55-16:20 |
IV-55 Elyes Dahmane Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients Thursday 14:55-16:20 |
IV-57 Camila De Almeida Modelling Irinotecan PK, efficacy and toxicities pre-clinically Thursday 14:55-16:20 |